Comparison of Insulin degludec vs. Insulin glargine using continuous glucose monitoring (CGM): Crossover study

Comparison of Insulin degludec vs. Insulin glargine using continuous glucose monitoring (CGM): Crossover study - Degludec vs. Glargine using CGM: Crossover study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010847

Enrollment

Registered

2013-05-31

Start date

2013-05-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

During Stage I, the D/G group received insulin degludec. After 1 month of treatment, patients were hospitalized for 4 days, and blood glucose levels were measured for two consecutive days using CGM. D

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes patients medicated insulin therapy for 3 month or longer

Exclusion criteria

Exclusion criteria: 1) severe renal dysfunction (serum creatinine level &#8805;2 mg/dL) 2) judged to be unsuitable for participation for medical reasons.

Design outcomes

Primary

Measure	Time frame
M-value, MAGE, mean glucose level etc.	—

Secondary

Measure	Time frame
U-CPR, BNP, PAI-1 etc.	—

Countries

Japan

Contacts

Public ContactSoichi Takeishi

Ichinomiyanishi Hospital Department of Endocrinology and Diabetes

souichi19811225@yahoo.co.jp0586-48-0077

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026